Skip to main content
. 2023 Jul 20;14:1241130. doi: 10.3389/fphar.2023.1241130

FIGURE 3.

FIGURE 3

Scatter plots of incremental QALYs and costs in the PSA at various adebrelimab prices. (A1) Results of PSA in model 1 for base-case from Chinese perspective (B1) Results of PSA in model 2 for base-case from Chinese perspective, (C1) Results of PSA in model 1 for scenario 1 from Chinese perspective (D1) Results of PSA in model 2 for scenario 1 from Chinese perspective, (E) Results of PSA in model 1 for scenario 2 from Chinese perspective (F) Results of OWSA in model 2 for scenario 2 from Chinese perspective. (A2) Results of PSA in model 1 for base-case from the US perspective (B2) Results of PSA in model 2 for base-case from the US perspective, (C2) Results of PSA in model 1 for scenario 1 from the US perspective (D2) Results of PSA in model 2 for scenario 1 from the US perspective.